EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean E Abraham iD, Karen Pinilla iD, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M Drewett, Rebecca Lucey iD, Alexander Fulton, Anne N Roberts, Joanna R Worley, Anita Chhabra iD und 33 weitere

Nature · 30.05.2024 · 629 (8014) · 1142-1148

DOI: 10.1038/s41586-024-07384-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nature, online erschienen am 08.04.2024. Verfasst von Jean E Abraham und 44 weiteren Autor:innen. Beteiligte Einrichtung: Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Phthalazines, Piperazines. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2 , who were germline BRCA 1 and BRCA2 wild type 3 . Here we report the results of the trial. Patients ( n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR) 4 , and secondary end points included event-free survival (EFS) and overall survival (OS) 5 . pCR was achieved in 51% of patients in the research arm and 52% in the control arm ( P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyPhthalazinesPiperazinesTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedAnthracyclinesCarboplatinGenes, BRCA1Genes, BRCA2PaclitaxelPathologic Complete ResponseProgression-Free SurvivalProspective StudiesSurvival AnalysisTime FactorsAdolescentYoung AdultBRCA1 ProteinBRCA2 Protein

Substanzen

AnthracyclinesCarboplatinPaclitaxelPhthalazinesPiperazinesBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Proteinolaparib

Autor:innen und Institutionen

  • Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk.
  • Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk.
  • Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.
  • Cambridge Cancer Trials Centre, University of Cambridge, Cambridge, UK.
  • Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

ORCID-Profile: Jean E Abraham, Karen Pinilla, Rebecca Lucey, Anita Chhabra, Wendi Qian, Marc Tischkowitz

Zitieren

APA

Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A. L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., …, & Earl, H. M. (2024). The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature, 629(8014), 1142-1148. https://doi.org/10.1038/s41586-024-07384-2

Vancouver

Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024;629(8014):1142-1148. doi:10.1038/s41586-024-07384-2

BibTeX
@article{Abraham2024,
  author = {Abraham, Jean E and Pinilla, Karen and Dayimu, Alimu and Grybowicz, Louise and Demiris, Nikolaos and Harvey, Caron and Drewett, Lynsey M and Lucey, Rebecca and Fulton, Alexander and Roberts, Anne N and Worley, Joanna R and Chhabra, Anita and Qian, Wendi and Vallier, Anne-Laure and Hardy, Richard M and Chan, Steve and Hickish, Tamas and Tripathi, Devashish and Venkitaraman, Ramachandran and Persic, Mojca and Aslam, Shahzeena and Glassman, Daniel and Raj, Sanjay and Borley, Annabel and Braybrooke, Jeremy P and Sutherland, Stephanie and Staples, Emma and Scott, Lucy C and Davies, Mark and Palmer, Cheryl A and Moody, Margaret and Churn, Mark J and Newby, Jacqueline C and Mukesh, Mukesh B and Chakrabarti, Amitabha and Roylance, Rebecca R and Schouten, Philip C and Levitt, Nicola C and McAdam, Karen and Armstrong, Anne C and Copson, Ellen R and McMurtry, Emma and Tischkowitz, Marc and Provenzano, Elena and Earl, Helena M},
  title = {The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer},
  journal = {Nature},
  year = {2024},
  volume = {629},
  number = {8014},
  pages = {1142--1148},
  doi = {10.1038/s41586-024-07384-2}
}
Kostenlos starten →